搜尋結果
1. 田先生的履歷. 田先生已從本公司的總裁助理調任為本公司副總裁,現時亦是中廣核鈾業發展副總經理。 項目部及施工管理中心工作。田先生於2016 年3月加入中國廣核集團有限公司,曾擔任體系管�. 部政策制度處制度業務經理。田先生於2018 年9月加入中廣核鈾業發展,曾擔任其下屬公司中廣核鈾業物流(北�. )有限公司的總經理及董事長。�. 田先生於2004 年7月畢業於西安交通大學建築環境與設備工程專業,獲得工學學士學位。 董事會謹藉此機會歡迎邱先生及田先生履任新職。 承董事會命. 中廣核礦業有限公司* 主席. 安軍靖. 香港,2024 年4 月10日.
- Parties
- Completion
- Management of the Target Company
- Profit distribution
- PROCEEDS FROM THE DEEMED DISPOSAL
- REASONS FOR AND BENEFITS OF THE DEEMED DISPOSAL
- INFORMATION ON THE COMPANY, TA PROSPERITY, THE JV PARTNER, THE TARGET COMPANY AND THE PROJECT COMPANY
TA Prosperity the JV Partner the Target Company the Project Company To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, the JV Partner and its ultimate beneficial owners are all third parties independent of the Company and its connected persons.
Completion of the Deemed Disposal took place on the even date of the Cooperation Development Agreement and the JV Partner and TA Prosperity shall thereafter share the profit and loss of the Target Company in proportion to their respective equity interest in the Target Company.
Significant matters of the Target Company (including but not limited to increase or reduction in capital, amendments to the articles, mergers, demergers and liquidation) shall be unanimously approved by all the shareholders of the Target Company. The board of directors of the Target Company shall consist of five directors, of whom two would be nomi...
The profit shall be distributed to the JV Partner and TA Prosperity in accordance with their respective equity interest in the Target Company.
The proceeds from the Deemed Disposal will be used to fund the Land Cost.
The Deemed Disposal allows the Group to diversify its risks in the development of the Land. The contribution of 40% of the Land Cost by the JV Partner improves the Group’s liquidity by reducing the Group’s contribution amount to the total Land Cost and allows allocation of its financial resources in other sectors. In light of the aforesaid, the Dir...
The Company The Company is a company incorporated in Hong Kong with limited liability, and the shares of which are listed on the Main Board of the Stock Exchange. The principal business activity of the Company is investment holding. The Group is engaged principally in the development of apartments, villas, office buildings and commercial properties...
On 23 April 2004, the Company received a winding up petition filed with the High Court of Hong Kong SAR by one of its creditors dated 19 April 2004. In view of the proposed restructuring being contemplated, the Board intends to apply to the court for adjournment of the winding up petition.
年二月的天津田邊董事會決議，天津田邊已向其當時股東派發一筆人民幣 113,876,767元的特別股息。 於簽訂產權交易合同之前，田邊三菱及力生製藥分別持有天津田邊的75.35%及
有關於二零二四年六月十四日舉行之 二零二三年度股東大會、 二零二四年第一次A股類別股東會及 二零二四年第一次H股類別股東會 投票表決結果之澄清公告. 茲提述麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (「 本公司」)日期為二零二四年六月十四日 ...
承董事會命 中國生物製藥有限公司 主席 謝其潤 香港，2024年6月25日 於本公告日期，本公司董事會包括六位執行董事，即謝其潤女士、謝炳先生、鄭翔玲女士、謝承潤 先生、謝炘先生及田舟山先生，以及五位獨立非執行董事，即陸正飛先生、李大魁先生、魯紅女 士、張魯夫先生及李國棟醫生。 Created Date. 6/25/2024 4:11:05 PM .
香港,二零二四年六月十四日代表董事會. 匯財金融投資控股有限公司. 主席. 田一妤女士. 於本公告日期,董事會成員包括執行董事兼董事會主席田一妤女士,執行董事兼本公司行政總裁廖夢婷女士,執行董事林霆女士,以及獨立非執行董事韓銘生先生、李筠翎女士及鄧澍焙先生。 同及個別地承擔全部責任。各董事在作出一切合理查詢後,確認就其所知及所信,本公告所載資料在各重要方面均屬準確完備,沒有誤導或欺詐成分,且並無遺漏任何事項,足以令致本公告�. 本公告將由刊登之日起在聯交所網址https://www.hkexnews.hk之「最新上市公司公告」網頁至少保存七日及於本公司網址www.finsofthk.com刊載。
